Summary
Eli Lilly & Company (LLY) has filed an 8-K report on January 14, 2025, to announce its participation in the 2025 J.P. Morgan Healthcare Conference. During this event, the company is scheduled to provide an update on its 2024 earnings guidance and unveil its revenue guidance range for 2025. This presentation will also include discussions on broader market trends relevant to the pharmaceutical sector. Investors should note that the information being shared is part of a fireside chat and will be accompanied by a press release (Exhibit 99.1) and presentation slides, all of which will be accessible via webcast on Lilly's Investor website. While this 8-K serves to disclose the upcoming events and materials, the provided information is furnished and not deemed "filed" under Section 18 of the Exchange Act, meaning it does not carry the same regulatory implications as formally filed financial statements. The company will make replays available for approximately 30 days.
Key Highlights
- 1LLY to participate in the 2025 J.P. Morgan Healthcare Conference on January 14, 2025.
- 2Company will provide an update on 2024 earnings guidance.
- 3LLY will issue its revenue guidance range for the full year 2025.
- 4Discussion will include overall market trends in the pharmaceutical industry.
- 5A press release (Exhibit 99.1) and presentation materials will be available.
- 6Webcast and replay of the presentation will be accessible on Lilly's Investor website.
- 7Information furnished is not considered 'filed' for Section 18 of the Exchange Act purposes.